Previous 10 | Next 10 |
Biocare Cardiac is the first-of-its-kind comprehensive cardiac disease management solution combining diagnostics, RPM, disease and lifestyle management, and telemedicine for cardiologists and patients. REDWOOD CITY, CA / ACCESSWIRE / October 26, 2022 / Biotricity, Inc. (NASDAQ:BTCY), a ...
REDWOOD CITY, CA / ACCESSWIRE / October 13, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that Waqaas Al-Siddiq, Founder and CEO, is scheduled to participate in a panel discussion...
Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future REDWOOD CITY, CA / ACCESSWIRE / October 4, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Com...
Bioflux-AI is an innovative artificial intelligence-driven (‘AI') system with real-time monitoring and prediction capabilities that will be used to investigate stroke episodes in Chronic Kidney Disease patients REDWOOD CITY, CA / ACCESSWIRE / September 7, 2022 / Biotricity Inc. (...
Biotricity press release ( NASDAQ: BTCY ): Q1 GAAP EPS of -$0.09. Revenue of $2.06M (+17.0% Y/Y). For further details see: Biotricity GAAP EPS of -$0.09, revenue of $2.06M
REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq...
REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 /bb Biotricity Inc. (NYSE:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call and webcast on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its...
Today, we take our first look at a small medical device maker called Biotricity. Impressive growth projections lie ahead for this Busted IPO as it recently launched several important new products. An investment analysis follows in the paragraphs below. Facts do not c...
Biotricity press release ( NASDAQ: BTCY ): Q4 Non-GAAP EPS of -$0.11 in-line. Revenue of $2.15M (+80.7% Y/Y) beats by $0.04M . For further details see: Biotricity Non-GAAP EPS of -$0.11 in-line, revenue of $2.15M beats by $0.04M
Company Reports Record Revenue and Improved Margins REDWOOD CITY, CA / ACCESSWIRE / July 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2022 f...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. East...